COMMUNIQUÉS West-GlobeNewswire
-
Equillium Receives Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of EQ504
05/10/2026 -
Eledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual Meeting
05/10/2026 -
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
05/10/2026 -
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05/10/2026 -
BridgeBio and Community Partners Launch Nationwide ATTR-CM Education Effort Ahead of World Amyloidosis Day
05/10/2026 -
iCell Gene Therapeutics Announces Upcoming Conference Presentations
05/10/2026 -
ORIC® Pharmaceuticals Announces Agreement with Cancer Research UK to Advance a Potential First-in-Class CIP2A-Targeted Therapy Into Clinical Development
05/10/2026 -
Major shareholder announcement - BlackRock, Inc.
05/10/2026 -
FDA Clears Motivista (CT-155), the First Authorized Treatment for Negative Schizophrenia Symptoms
05/10/2026 -
Cerene® Cryotherapy Brings Free Mother-Daughter Period Education Brunch to Indianapolis Area
05/10/2026 -
Genmab and AbbVie Announce Epcoritamab in Combination with R-CHOP Demonstrates Statistically Significant Improvement in Progression-Free Survival in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
05/10/2026 -
Baylor Genetics Selected as the Lead Sequencing Partner for Florida’s Sunshine Genetics Pilot Program Launch
05/10/2026 -
Frederick Breathe Free Celebrates Dr. Jamie Oberman’s Recognition as a 2026 Castle Connolly Top Doctor
05/10/2026 -
Zealand Pharma – Completion of share buy-back program and related transactions (week 40 and 41, 2026)
05/10/2026 -
Global Alzheimer's Platform Foundation Names New Medical Director at Tampa Research Site
05/10/2026 -
Declaration of shares and voting rights - Status as of September 30, 2026
05/10/2026 -
Déclaration d’actions et de droits de vote - Statut au 30 septembre 2026
05/10/2026 -
Efficacy of aprocitentan in patients across the cardiometabolic disease spectrum including obesity to be presented at AHA Hypertension
05/10/2026 -
Sironax Named to Fierce Biotech’s “Fierce 15” List of the Most Innovative and Promising Private Biotechs of 2026
05/10/2026
Pages